Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vacc-4x + Lenalidomide in HIV-1
NCT01704781Phase 2Completed
- Sponsor
- Immunor
- Start
- Sep 2012
- Primary completion
- Aug 2014
- Modality
- Peptides, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus type 1 infection (HIV-1) comparing Lenalidomide Dose Escalation, Vacc-4x + Lenalidomide and Vacc-4x + Placebo (3 arms). Primary endpoints: Highest Tolerated Dose of Lenalidomide at 31 days and CD4 Counts Over Time at Week 26. Started Sep 2012; status: completed.
02
Drugs
lenalidomideVacc-4x
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01704781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01704781.